October 2024

We changed how we manage immunoglobulin therapies for most commercial members starting Oct. 1 (PDF)

Prior authorization approvals now valid for 180 days for PTs and OTs in Category A (PDF)

e-referral system out of service for maintenance overnight October 19-20 (PDF)

You can now add comments when answering InterQual Connect questions in the e-referral system (PDF)

Tremfya IV will require prior authorization for Medicare Advantage members starting Dec. 2 (PDF)

Otulfi to have a prior authorization requirement for most members (PDF)

Register now for Oct. 10 webinar on prior authorization programs with Carelon (PDF)

Select a recommended procedure when answering InterQual Connect questions in the e-referral system (PDF)

September 2024

Updated forms now available for submitting prior authorization requests for post-acute care services (PDF)

Tezspire to have a site-of-care requirement for most commercial members starting Jan. 1 (PDF)

Changes to the Breast Elastography Trigger questionnaire in the e-referral system (PDF)

Facilities can now enter post-acute care prior authorization requests for Medicare Advantage members in e-referral (PDF)

Issue resolved: Don’t add comments when answering InterQual Connect questions in the e-referral system (PDF)

2025 coverage change for GLP-1 drugs to treat obesity (PDF)

Preferred product for Hemgenix for most commercial members starting Nov. 11 (PDF)

Beqvez to require prior authorization for Federal Employee Program non-Medicare members starting Jan. 1 (PDF)

Changes to preferred drug designations under the medical benefit for most members, starting Jan. 1 (PDF)

Medical benefit oncology drugs that will require prior authorization through OncoHealth starting Jan. 1 (PDF)

Elrexfio, Lunsumio, Talvey and Tecvayli will have additional requirements for most commercial members (PDF)

Ocrevus Zunovo SC to have requirements for most commercial members starting Oct. 3 (PDF)

Update: Tremfya IV to require prior authorization for most commercial members starting Sept. 26 (PDF)

e-referral system out of service for maintenance overnight September 21-22 (PDF)

Jubbonti and Wezlana to require prior authorization for Medicare Advantage members starting Nov. 3 (PDF)

Rituximab preferred agents to change for Medicare Advantage members starting Jan. 1 (PDF)

August 2024

Additional musculoskeletal spinal procedures to require prior authorization for Blue Cross commercial members starting Nov. 27 (PDF)

Update: Learn more about changes related to post-acute care services for Medicare Advantage members starting Oct. 1 (PDF)

Pavblu to require prior authorization for most commercial members starting Sept. 5 (PDF)

Sept. 2 holiday closure: How to submit authorization requests for inpatient admissions (PDF)

Update: Prior authorization changes for blepharoplasty, enteral nutrition, percutaneous left atrial appendage and varicose vein treatment starting Sept. 8 (PDF)

Niktimvo IV to require prior authorization for most commercial members starting Sept. 5 (PDF)

Zynyz and Talvey to require prior authorization for URMBT members with Blue Cross non-Medicare plans (PDF)

Enzeevu to require prior authorization for most commercial members starting Aug. 29 (PDF)

PiaSky and Tecelra will require prior authorization for Medicare Advantage members starting Oct. 1 (PDF)

e-referral system out of service for maintenance overnight August 17-18 (PDF)

Physician appointment access survey in process (PDF)

Tecelra to require prior authorization for most commercial members starting Aug. 15 (PDF)

July 2024

Preferred immune globulin products for Medicare Advantage members to change starting Nov. 1 (PDF)

Rytelo to require prior authorization for most commercial members starting Aug. 8 (PDF)

Update: Changes coming for select weight loss drugs for some commercial members (PDF)

Blue Cross Behavioral Health no longer requires autism diagnostic re-evaluations (PDF)

Guidelines for billing Avastin for Blue Cross and BCN commercial members (PDF)

Epysqli to require prior authorization for most commercial members starting Aug. 8 (PDF)

Changes to the BCN referral and authorization requirements for Michigan providers document (PDF)

Tyenne, Tofidence and Zinplava to have a site-of-care requirement for most commercial members starting Nov. 1 (PDF)

Rytelo will require prior authorization for Medicare Advantage members starting Aug. 1 (PDF)

Updated TurningPoint medical policies for musculoskeletal and pain management procedures (PDF)

Release schedule for eviCore category assignments and practitioner performance summaries for PTs and OTs (PDF)

Kisunla and Ohtuvayre will require prior authorization for Medicare Advantage members starting July 15 (PDF)

Kisunla to require prior authorization for most commercial members starting July 18 (PDF)

e-referral system unavailable on two weekends in July (PDF)

Ahzantive, Nypozi and Pyzchiva to require prior authorization for most commercial members starting July 18 (PDF)

Home health care services won’t require prior authorization for Medicare Advantage members starting Oct. 1 (PDF)

We’re changing how we manage immunoglobulin therapies for most commercial members starting Oct. 1 (PDF)

June 2024

Yimmugo and Piasky to require prior authorization for most commercial members starting July 11 (PDF)

July 4-5 holiday closure: How to submit authorization requests for inpatient admissions (PDF)

Utilization management phone closed on June 28 until 1 p.m. (PDF)

Questionnaire changes in the e-referral system starting June 23 (PDF)

Step therapy requirements added for Soliris and Ultomiris for Medicare Advantage members with PNH starting Sept. 16 (PDF)

Lamzede and Vyjuvek to have requirements for URMBT members with Blue Cross non-Medicare plans (PDF)

June 19 holiday closure: How to submit authorization requests for inpatient admissions (PDF)

e-referral system out of service for maintenance overnight June 15-16 (PDF)

Reminder: Bill HCPCS code J3590 for off-label intravitreal use of Avastin for Blue Cross commercial members (PDF)

Beqvez will have additional requirements for most commercial members (PDF)

Vyjuvek will have additional requirements for most commercial members starting July 22 (PDF)

Bkemv to require prior authorization for most commercial members starting June 13 (PDF)

Alyglo has requirements for Federal Employee Program non-Medicare members as of June 1 (PDF)

Update: Changes coming for select weight loss drugs for some commercial members (PDF)

Soliris and Ultomiris to have a step therapy requirement for commercial members (PDF)

May 2024

Opuviz and Yesafili to require prior authorization for most commercial members starting June 6 (PDF)

Medicare implantable ambulatory event monitors questionnaire removed from the e-referral system (PDF)

Hemlibra to have a quantity limit requirement for most commercial members (PDF)

Changes to the Hyperbaric oxygen therapy questionnaires in the e-referral system (PDF)

Step therapy requirement added for Saphnelo for Medicare Advantage members starting Sept. 1 (PDF)

May 27 holiday closure: How to submit authorization requests for inpatient admissions (PDF)

Tricia A. Keith to succeed Daniel J. Loepp as president and CEO of Blue Cross Blue Shield of Michigan (PDF)

New information about Winrevair SC for commercial members (PDF)

We’ll use 2024 InterQual criteria starting Aug. 1 (PDF)

Changes coming to prior authorization process for postacute care services for Medicare Advantage members (PDF)

Loqtorzi to have requirements for most members starting Aug. 15 (PDF)

Spevigo SC and Tyenne will require prior authorization for Medicare Advantage members starting July 1 (PDF)

Beqvez will require prior authorization for Medicare Advantage members starting June 1 (PDF)

Syfovre, Izervay and Elfabrio to have requirements for URMBT members with Blue Cross non-Medicare plans (PDF)

Update: Prior authorization no longer required for autism-related PT, OT, ST and physical medicine services for BCN commercial members (PDF)

e-referral system unavailable on two weekends in May (PDF)

Step therapy requirement added for botulinum toxins for Medicare Advantage members starting Aug. 5 (PDF)

Update: Beqvez to require prior authorization for most commercial members starting May 9 (PDF)

April 2024

Pemfexy and Pemrydi RTU to have additional step therapy requirements for most members (PDF)

Changes to the Facial feminization surgery and chondrolaryngoplasty questionnaire in the e-referral system (PDF)

Hercessi to require prior authorization for most commercial members starting May 16 (PDF)

Save time: Submit only required information about inpatient acute care medical / surgical admissions (PDF)

Additional drugs to have a site-of-care requirement for some commercial members, starting Aug. 1 (PDF)

Guidelines for using the Autism diagnostic evaluation results form (PDF)

Change to prior authorization process for Blue Cross commercial members in Michigan whose plans have local provider networks (PDF)

TurningPoint opens peer-to-peer reviews to advanced practice providers for musculoskeletal and pain management procedures (PDF)

Omvoh SC and IV to have a step therapy requirement for most commercial members starting June 3 (PDF)

Update: Spevigo SC to have requirements for most commercial members starting April 25 (PDF)

e-referral system out of service for maintenance overnight April 20-21 (PDF)

Amtagvi will have additional requirements for most commercial members, starting May 28 (PDF)

Procedure codes that require prior authorization through BCN (PDF)

Cosentyx IV to have a site-of-care requirement for most commercial members starting July 1 (PDF)

Update: Winrevair to require prior authorization for Medicare Advantage members starting May 1 (PDF)

Vyjuvek to have a site-of-care requirement for most commercial members starting April 4 (PDF)

March 2024

Questionnaire changes in the e-referral system starting March 31 (PDF)

Cinryze, Elfabrio and Evkeeza to have a site-of-care requirement for most commercial members starting July 1 (PDF)

Columvi, Daxxify and Qalsody to require prior authorization for URMBT members with Blue Cross non-Medicare plans (PDF)

March 29 holiday closure: How to submit authorization requests for inpatient admissions (PDF)

Lenmeldy to require prior authorization for most commercial members starting March 28 (PDF)

Step therapy requirement to be added for VPRIV and Elelyso for Medicare Advantage members starting June 1 (PDF)

Tofidence will require prior authorization for Medicare Advantage members starting May 1 (PDF)

Elrexfio and Talvey to require prior authorization for most members starting June 20 (PDF)

Explanation of lifestyle modification for weight loss drugs (PDF)

Wyost SC, Jubbonti SC and Tyenne IV and SC to require prior authorization for most commercial members starting March 21 (PDF)

e-referral system out of service for maintenance overnight March 16-17 (PDF)

Update: Preferred product for Zynteglo for most commercial members starting April 19 (PDF)

Udenyca Onbody to require prior authorization for most commercial members effective immediately (PDF)

Update: Prior authorization requirements are changing for musculoskeletal pain management and spinal procedure codes (PDF)

We’re changing how we manage Entyvio SC and Omvoh SC, starting March 1 (PDF)

Additional drugs to require prior authorization for Medicare Advantage members starting April 1 (PDF)

February 2024

Medicare Plus Blue PPO Provider Manual update coming in April 2024 (PDF)

Update: Prior authorization requests for behavioral health services (PDF)

Changes to the Gastric stimulation and Breast reconstruction questionnaires in the e-referral system (PDF)

Update: Amtagvi to require prior authorization for most commercial members starting Feb. 29 (PDF)

Additional preferred products for Soliris and Ultomiris for most commercial members starting April 1 (PDF)

e-referral system out of service for maintenance overnight Feb. 17-18 (PDF)

Don’t submit referrals for members with BCN point-of-service plans (PDF)

Additional cardiology services to require prior authorization through Carelon for commercial members, starting May 11 (PDF)

Call Blue Cross Behavioral Health if you need additional ABA units to bill approved authorizations (PDF)

January 2024

Starting in March, we’ll no longer attach approval letters to Blue Cross commercial inpatient authorizations (PDF)

We’re no longer mailing some letters related to Medicare Advantage inpatient admissions (PDF)

Pemfexy to have step therapy requirements starting April 26 (PDF)

Omvoh to have a site-of-care requirement for most commercial members starting May 1 (PDF)

Include complete clinical information when submitting prior authorization requests for weight loss drugs (PDF)

Updated: Entyvio, Omvoh and Wezlana to require prior authorization for most commercial members (PDF)

Questionnaire changes in e-referral starting Jan. 28 (PDF)

In the Blue Cross Behavioral Health provider portal, complete only the required fields when searching for a member (PDF)

Starting March 1, some continuous glucose monitor products will require prior authorization (PDF)

Updated: Alyglo to require prior authorization for most commercial members starting Jan. 18 (PDF)

Cabenuva to have requirements for most commercial members starting May 1 (PDF)

Email us if you’re having technical problems using the Blue Cross Behavioral Health provider portal (PDF)

e-referral system out of service for maintenance overnight Jan. 20-21 (PDF)

Continuity of care arrangements are expanded to Medicare Advantage members (PDF)

Requirements changing for some medical benefit drugs for Medicare Advantage members (PDF)

Blue Cross Behavioral Health to reinstate requirements; providers can submit authorization requests (PDF)

January 2, 2024: Changes to ereferrals.bcbsm.com (PDF)

Jan. 15 holiday closure: How to submit authorization requests for inpatient admissions (PDF)